Comparing two chemo drugs for liver cancer TACE
Part of Cancer, Digestive system clinical trials.
This study compares two chemotherapy drugs, idarubicin and doxorubicin, given during a liver cancer treatment called TACE (a procedure that delivers chemo directly to the tumor). It is for people with early-stage liver cancer who have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have been diagnosed with liver cancer (HCC) that hasn't spread outside the liver.
- You have 5 or fewer tumors, and the largest one is 5 cm (about 2 inches) or smaller.
- You have not had any previous treatment for liver cancer.
- Your liver function is good enough (Child-Pugh class A or B) and you are generally active (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial compares two treatments for liver cancer that cannot be removed by surgery: TACE (a procedure that blocks the tumor's blood supply) plus an oral drug cocktail versus TACE plus standard immunotherapy. The goal is to see which approach works better and is safer.
This trial compares two types of tiny beads used in a liver cancer treatment called TACE to see which works better. If you have liver cancer that needs TACE and your liver is still working fairly well, you may be able to join.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
This trial tests whether combining TACE (a procedure that blocks blood supply to the tumor) with three medicines (SHR-8068, adebrelimab, and bevacizumab) works better than TACE alone for people with incurable liver cancer that can't be removed surgically.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.